Human Genome Epidemiology Literature Finder
Records 1 - 16 (of 16 Records) |
Query Trace: Lung Neoplasms and CDA[original query] |
---|
Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides, nucleotides & nucleic acids 2008 Jun 27 (6): 720-5. Giovannetti E, Laan A C, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S, Falcone A, Danesi R, Peters G |
Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands) 2009 Jan 63 (1): 121-7. Soo Ross A, Wang Ling Zhi, Ng Swee Siang, Chong Pei Yi, Yong Wei Peng, Lee Soo Chin, Liu Jian Jun, Choo Tai Bee, Tham Lai San, Lee How Sung, Goh Boon Cher, Soong Rich |
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 14 (6): 1797-803. Tibaldi Carmelo, Giovannetti Elisa, Vasile Enrico, Mey Valentina, Laan Adrie C, Nannizzi Sara, Di Marsico Roberta, Antonuzzo Andrea, Orlandini Cinzia, Ricciardi Simona, Del Tacca Mario, Peters Godefridus J, Falcone Alfredo, Danesi Roma |
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clinical pharmacokinetics 2010 Aug 49 (8): 549-58. Sugiyama Emiko, Kaniwa Nahoko, Kim Su-Ryang, Hasegawa Ryuichi, Saito Yoshiro, Ueno Hideki, Okusaka Takuji, Ikeda Masafumi, Morizane Chigusa, Kondo Shunsuke, Yamamoto Noboru, Tamura Tomohide, Furuse Junji, Ishii Hiroshi, Yoshida Teruhiko, Saijo Nagahiro, Sawada Jun-Ic |
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. European journal of clinical pharmacology 2010 Jun 66 (6): 611-7. Maring Jan Gerard, Wachters Floris M, Slijfer Monique, Maurer J Marina, Boezen H Marike, Uges Donald R A, de Vries Elisabeth G E, Groen Harry J |
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012 Mar 23 (3): 670-7. Tibaldi C, Giovannetti E, Tiseo M, Leon L G, D'Incecco A, Loosekoot N, Bartolotti M, Honeywell R, Cappuzzo F, Ardizzoni A, Peters G |
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer chemotherapy and pharmacology 2011 May . Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH |
Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenetics and genomics 2012 Feb 22 (2): 105-16. Li Liang, Schaid Daniel J, Fridley Brooke L, Kalari Krishna R, Jenkins Gregory D, Abo Ryan P, Batzler Anthony, Moon Irene, Pelleymounter Linda, Eckloff Bruce W, Wieben Eric D, Sun Zhifu, Yang Ping, Wang Liew |
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Dec 6 (12): 2018-26. Ludovini Vienna, Floriani Irene, Pistola Lorenza, Minotti Vincenzo, Meacci Marialuisa, Chiari Rita, Garavaglia Daniela, Tofanetti Francesca Romana, Flacco Antonella, Siggillino Annamaria, Baldelli Elisa, Tonato Maurizio, Crinò Luc |
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2012 May 118 (9): 2466-75. Joerger Markus, Burgers Sjaak A, Baas Paul, Smit Egbert F, Haitjema Tjeerd J, Bard Martin P L, Doodeman Valerie D, Smits Paul H M, Vincent Andrew, Huitema Alwin D R, Beijnen Jos H, Schellens Jan H |
Genetic polymorphisms of XPD and CDA and lung cancer risk. Oncology letters 2012 Aug 4 (2): 247-251. Zhou Min, Wan Huan-Ying, Gao Bei-Li, Ding Yong-Jie, Jun Rong-X |
Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. Genetics and molecular research : GMR 2014 13 (2): 3310-8. Zhou M, Ding Y J, Feng Y, Zhang Q R, Xiang Y, Wan H |
The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis. The International journal of biological markers 0 29 (3): e224-32. Li Hui, Wang Xiangling, Wang Xiuw |
Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer. The International journal of biological markers 2019 Oct 1724600819882940. Li Jing, Xu Dan, Huang Jian, Wang Yan-Na, Ma Xiao-Ping, Lin Zhi-Yi, Gong Pi |
Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients. Neoplasma 2021 Mar . Hu Lili, Mao Xintong, Gao Chao, Xu Yinhai, Li Chenglin, Wang Tao, Lv Dongm |
Differences in actionable genomic alterations between brain metastases and non?brain metastases in patients with non?small cell lung cancer. International journal of oncology 2022 Sep 61 (3): . Nian Rui, Jiang Huihui, Zhao Jiangman, Hou Wanle, Zhang Hua, Ma Jiangtao, Lv Pengbiao, Jiang Lisha, Wang Yongpan, Xu Yue, Wu Shouxin, Lou Jingwei, Li Wanj |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: